Ibogaine treatment and the case of Presley Gerber

Presley Gerber, the son of Cindy Crawford and Rande Gerber, had been using ibogaine, a psychoactive compound, as part of his treatment for addiction before his death on September 20, 2026. Gerber, who was 27, died at a sober living facility in Los Angeles from a suspected overdose, according to the Santa Monica Police Department.

Ibogaine's role in addiction treatment

Ibogaine is a powerful psychoactive substance derived from a Central African shrub. It has been used for decades to treat substance use disorders, particularly for its ability to alleviate opioid withdrawal symptoms and cravings, often after just one session. Joseph Barsuglia, a psychologist with extensive research experience on ibogaine, noted its unique capacity to stop opioid withdrawal, a claim unmatched by currently approved medications.

The compound's potential was first discovered in 1962 when Howard Lotsof, a heroin-addicted 19-year-old, experimented with ibogaine and found his cravings disappeared. Lotsof later patented its use for addiction treatment in 1985 and advocated for further research, although FDA-approved trials have not been conducted due to funding challenges.

Legal status and recent developments

Ibogaine is illegal in the United States and many European countries, prompting Americans to seek treatment in places like Mexico where it is legal. However, recent developments suggest a shift in the U.S. stance. In April 2026, former President Donald Trump signed an executive order to expedite research into psychedelic treatments, specifically naming ibogaine. This led to the FDA commencing its first U.S.-based trials of an ibogaine-derived drug.

Mechanism and effects

The exact mechanism of ibogaine is not fully understood, but it is known to impact the brain's reward and pleasure systems. By releasing a natural growth factor and modulating neural pathways, ibogaine helps restore dopamine function and reduce cravings, according to Barsuglia. Unlike methadone or suboxone, which require daily administration, ibogaine appears to repair the brain circuitry damaged by addiction.

Jonathan Dickinson, CEO of Ambio Life Sciences, explained that ibogaine increases the sensitivity of the body's opioid network, potentially reducing tolerance in individuals with high opioid tolerance. However, the treatment is intense, often involving 18 to 36 hours of deep hallucinations and emotional upheaval, making recreational use rare.

Challenges to approval

Since 1970, ibogaine has been classified as a Schedule 1 drug in the U.S., indicating no accepted medical use and a high potential for abuse. Financial disincentives have also hindered its approval, as ibogaine cannot be patented and typically requires only a single administration, limiting pharmaceutical companies' ability to recoup the costs of clinical trials.

Despite these challenges, there are signs of change. Several U.S. states, including Mississippi, Oklahoma, and Tennessee, have recently passed legislation to fund ibogaine trials, indicating growing interest in its potential benefits.

Why it matters

The case of Presley Gerber underscores the ongoing debate over ibogaine's role in addiction treatment. While some see it as a promising solution for opioid addiction, its legal status and the lack of comprehensive research continue to pose significant challenges. As the U.S. begins to explore ibogaine through FDA trials, its future in addiction treatment remains uncertain.

The evolving regulatory landscape and increasing legislative interest suggest that ibogaine could play a more prominent role in addiction treatment in the coming years.